Quantcast

Reportlinker Adds Pharmacodynamic Assays

December 8, 2009

NEW YORK, Dec. 8 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmacodynamic Assays

http://www.reportlinker.com/p0167260/Pharmacodynamic-Assays.html

Pharmacodynamic assays are assays that provide methods for quickly screening cell samples for a pharmacodynamic effect to a drug or test agent. These assays inform drug development decisions by providing evidence of drug action on molecular targets.

Pharmacodynamic assay development has become an increasingly lucrative area of product development for research supply companies, as demand for the assays has risen following recent introduction of Phase 0 trials by the FDA. Phase 0 trials are known as human microdosing studies and are designed to speed up the development of promising drugs by establishing early on whether they interact with their expected targets.

The NCI recently requested that qualified small businesses submit proposals to develop pharmacodynamic assays for measuring a number of high-priority molecular targets. (For a list of the targets of interest to NCI, see: http://sbir.cancer.gov/). NCI’s goal is to support development of new rigorous, validated assays to measure molecular-level response to treatment, especially real-time assays that could be used to rapidly assess response to treatment during clinical trials.

This market report characterizes the rapidly growing pharmacodynamic assays market, including:

* Market segmentation by application

* Examination of validated assays and assays under development

* Quantitative U.S. and International market size analysis

* Analysis of market growth rates and future projections

* In-depth analysis of emerging trends and opportunities

* A critique of high-priority molecular targets for assay development

* Research product opportunities & suggestions

In summary, it provides detailed guidance for companies that wish to develop pharmacodynamic assays to supplement their traditional research supplies or bio-pharmaceutical product development.

I. Pharmacodynamics Assays

A. Definition

B. History

1. Impact of Phase 0 Legislation

2. SBIR Support of Pharmacodynamic Assay Development

C. Increasing Participation from Research Supply Companies

1. Natural Extension of Product Lines

2. A Response to Potential Profits

II. Market Segmentation of by Application

A. Streamlined Drug Development Processes for Pharmaceutical Companies

B. Phase 0 Clinical Trials

C. Patient Stratification during Clinical Trials (Phase I-IV)

D. Prediction of Cancer Re-Occurrence

E. Insights into the Basis of Cytotoxic Response to Existing Cancer Therapies

F. Pharmacodynamic Monitoring of Immunosuppressive Drugs

III. Market Environment

A. High Market Penetration Assays

B. Recently Validated Assays

C. Assays under Development

IV. High-priority Molecular Targets for Assay Development

V. Competitive Analysis

A. Early Entrants

B. Dominant Competitors

C. Recent Market Players

VI. Analysis of Grant Rates / Trends in Funding

A. Trailing 5 Year Analysis

B. Projected 5 Year Analysis

VII. Market Size Determination for Pharmacodynamic Assays

A. Methods

B. Worldwide Annual Market Size

C. U.S. Annual Market Size

VIII. Market Growth Rates & Trend Analysis

A. Experimental Approach

B. Growth Rates

C. Trend Analysis

IX. Market Projections

X. Product Development Opportunities & Suggestions

A. Pre-Clinical Applications (Research-Use Only)

1. Angiogenesis

2. DNA Damage/Apoptosis

3. Other

B. Clinical Applications

To order this report:

Biotechnology Industry: Pharmacodynamic Assays

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus